Monoclonal antibodies targeting tumor surface antigens such as HER2/neu, CD20, EGF receptor and CD52, for example, are effective for the treatment of other malignancies, through immune cell-dependent and independent mechanisms [8]. The gene discussed is ERBB2; the disease is neoplasm.